文献速递白血病

青少年和年轻成人急性淋巴细胞白血病:GIMEMA LAL-1308 II期试验最终结果

Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
PubMed 文献 · Am J Hematol · 2020-12-29

Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) represent a unique patient population with specific characteristics and needs. Growing evidences suggest that pediatric-inspired approaches improve the outcome in AYA.…

要点

  • 儿童样方案在青少年和年轻成人Ph阴性ALL中可行,诱导死亡率2.7%。
  • 48个月OS和DFS分别为60.3%和60.4%,T-ALL优于B-ALL。
  • TP1和TP2的分子MRD<10^-3均与显著更好的OS和DFS相关。

核心结论

  • 儿童样且以MRD为导向的方案对Ph阴性青少年和年轻成人ALL患者可行且有效,并证实特定时间点MRD的预后价值。

主要发现

  • 完全缓解率92%,诱导死亡2.7%,巩固后阶段无死亡。
  • 48个月OS和DFS分别为60.3%和60.4%。
  • T-ALL的OS和DFS均显著优于B-ALL。
  • TP1分子MRD<10^-3者OS 77% vs 39%,DFS 71.9% vs 34.4%;TP2相应为OS 74.5% vs 30.6%,DFS 71.5% vs 25.7%。
  • 与历史GIMEMA LAL-2000和LAL-0904方案相比,OS和DFS均显著改善。

临床怎么用

  • 该儿童样方案可用于Ph阴性青少年和年轻成人ALL,并根据诱导IA结束和巩固IB结束时的MRD调整巩固后治疗强度。

局限性

  • 与历史方案比较可能存在混杂,非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) represent a unique patient population with specific characteristics and needs. Growing evidences suggest that pediatric-inspired approaches improve the outcome in AYA. These results prompted the design of a pediatric AIEOP-BFM ALL 2000-based regimen - the GIMEMA LAL-1308 protocol - for newly diagnosed AYA (range 18-35 years) with Philadelphia negative (Ph-) ALL. The protocol included minimal residual disease (MRD) analysis at two different time-points (TP), that is, at the end of induction IA and consolidation IB, and a modulation in post-consolidation intensity according to MRD. Seventy-six patients were eligible between September 2010 and October 2014. The regimen was well tolerated, with 2.7% induction deaths and no deaths in the post-consolidation phase. The complete response (CR) rate was 92%; the 48-month overall survival (OS) and disease-free survival (DFS) were 60.3% and 60.4%. Both OS and DFS were significantly better in T-ALL than B-ALL. A molecular MRD <10-3 at TP1 was associated with a significantly better OS and DFS (77% vs 39% and 71.9% vs 34.4%, respectively);similar results were documented at TP2 (OS and DFS 74.5% vs 30.6% and 71.5% vs 25.7%, respectively). The LAL-1308 results were compared to those from similar historic AYA populations undergoing the two previous GIMEMA LAL-2000 and LAL-0904 protocols. Both OS and DFS improved significantly compared to the two previous protocols. These results indicate that this pediatric-inspired and MRD-oriented protocol is feasible and effective for Ph- AYA ALL patients, and underline the prognostic value of MRD determinations at specific TPs.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Testi AM, Canichella M, Vitale A, et al. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial. Am J Hematol. 2020. PMID: 33284999. doi:10.1002/ajh.26066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。